Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
(Neo)adjuvant erlotinib plus cisplatine verbetert uitkomsten bij stadium III NSCLC
okt 2018 | Longoncologie